A) that in the near future (next year or two) the SOC (both in Europe and the US) for atrial fib anti-coag drugs will be something other than warfarin.
B) that even sooner than the above timeframe the majority of patients with atrial fib being prescribed their first anti-coag will get non-warfarin. This may have already happened (and this was part of the question I was asking) - but I don't know.
What I found surprising was dew's contention that the majority of atrial fib patients (the combo of newly diagnosed, long term users, ...) taking an anti-coag are, as of, say, Aug 2012, already taking a non-warfarin anti-coag. It implies a high rate of switching in just a year or two of patients that have been successfully taking warfarin for, on average, many years.
Why do I care? Because if the switch did happen as quickly as dew believes then I would like to know what factor (cultural? Political? Budgetary? Patient preference? ...) I miscalibrated and why doctors are able to live with such drawbacks as lack of reversibility and age related issues (I know for a fact that doctors in the US are leery of precisely these issues)
PS Haven't read Dew's response yet. Taking them one at a time after regaining I internet contract.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.